Meeting
2023 ASCO Annual Meeting
Long-term clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test.
Authors
Adam H Buchanan
Geisinger, Danville, PA
Adam H Buchanan , Anne Marie Lennon , Seema P Rego , Omair A Choudhry , Paul Z Elias , Jennifer R Sadler , Joshua D Cohen , Christopher B Douville , Ashley M Honushefsky , Alison Klein , Zachary M Salvati , Kathleen Sheridan , Cristian Tomasetti , Eric S Wagner , Carroll N Walter , Elliot K. Fishman , Kenneth W. Kinzler , Bert Vogelstein , Tomasz M. Beer , Nickolas Papadopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3037)
DOI
10.1200/JCO.2023.41.16_suppl.3037
Abstract #
3037
Poster Bd #
235
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Clinical outcomes of soft tissue sarcoma in the Philippines: A single-center experience.
First Author: Omar Paningbatan Maaño
Poster
2022 ASCO Annual Meeting
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
First Author: Laura Spring
Poster
2021 ASCO Annual Meeting
Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test.
First Author: Tomasz M. Beer
Poster
2017 Gastrointestinal Cancers Symposium
A study on thromboembolism of patients with pancreatic cancer.
First Author: Kwan Yu LAM